Xcout Intel
BeiGene
Beigene, now known as BeOne Medicines, is a multinational oncology company. It specializes in biotechnology research and the development of cancer treatment drugs, with headquarters located in Cambridge, Massachusetts.
Subscribe to see BeiGene’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
BeiGene at a glance
BeiGene is a biotech company headquartered in United States. Xcout tracks 39 named people at BeiGene, including Lai Wang, Ph.D. (President, Global Head of Research & Development). Xcout recorded 146 job postings from BeiGene in the last 90 days, naming tools such as Power BI, SAP, Databricks.
BeiGene leadership
- Lai Wang, Ph.D.President, Global Head of Research & Development
- Xiaobin Wu, Ph.D.President & Chief Operating Officer
- Aaron RosenbergChief Financial Officer
- Marcello DamianiChief Technology Officer
- Amit Agarwal, M.D., Ph.D.Chief Medical Officer, Hematology
- Han Ma, M.D., Ph.D.Chief Safety Officer & Senior Vice President, Global Patient Safety
33 more named people on record for BeiGene, with roles, board committees and tenure — see the full roster →
Hiring at BeiGene
Xcout recorded 146 job postings from BeiGene in the last 90 days, from a hiring record Xcout has kept since June 2026.
Tools named in BeiGene's job postings
The weekly hiring trend, the roles and locations behind it — see BeiGene's hiring signals →
Recent BeiGene news
Hiring vs the trend
Based on 90 job postings in the last 8 weeks (10 Aug – 4 Oct 2026), compared with 168 enterprise healthcare companies.
This describes a hiring pattern — how often BeiGene’s job postings ask for AI skills, and how that changed against the previous 8 weeks, ranked among its peers. It says nothing about the company’s products or performance.
Signed-in members see the AI-skill share and its change with peer percentiles, role mix, posting momentum and advertised US pay against the market.
Tech stack
BeiGene competitors
A few of BeiGene's closest competitors — see the full list of competitors and alternatives →
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK targeting chimeric degradation activation compound active against wild type and mutant BTK; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187 and BG-C0902, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company was formerly known as BeiGene, Ltd. and changed its name to BeOne Medicines AG in May 2025. BeOne Medicines AG was founded in 2010 and is based in Basel, Switzerland.
Be Biopharma is a biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on developing engineered B cell therapies.
Beijing Avistone Biotechnology Co., Ltd. is a commercial-stage biopharmaceutical company focused on the research, development, and commercialization of oncology treatments. The company develops innovative targeted drugs, such as plemitinib and abelmetinib, to serve cancer patients globally.
NBE-Therapeutics is a biotechnology company founded in 2012 and headquartered in Basel, Switzerland, focused on developing antibody-drug conjugates for oncology treatments.
Checkmate Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on developing proprietary technology to stimulate the immune system to combat cancer.
Curis, Inc. is a biotechnology company headquartered in Lexington, Massachusetts. The company is engaged in the research and development of drug candidates for the treatment of human cancers.
Get BeiGene's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on BeiGene in Xcout Intel
- 39 named people with titles, LinkedIn and board committees
- Weekly hiring history and the mix of roles behind it
- 2 corporate events with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access